ClinicalTrials.gg
Not yet recruitingNCT07083830ECPUpdated Nov 2, 2026

ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants

A Phase 1 interventional study of ECP-DL treated mononuclear cell infusion in Kidney Transplant Failure and Rejection and Kidney Transplant; Complications, sponsored by Northwestern University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Northwestern University · Phase 1, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a phase 1 trial, 36 month duration for subjects with end-stage renal disease (ESRD). The objectives of the trail are1) Determine the safety of ECP-DL cell infusion in living donor renal transplant recipients. 2) Determine rates of graft rejection and compare to historical controls.

One week prior to planned LDK transplant the donor and recipient pair will be seen for ECP-DL preparation and infusion. Donors will undergo one single unstimulated peripheral blood mononuclear cell collection using the THERAKOS® CELLEX® Photopheresis System; the cell product will then undergo ECP treatment to make ECP-DL, which will then be infused into the recipient. One week later, recipients (n=12) will undergo LDK transplant using standard of care maintenance immunosuppression without antibody induction therapy. Subsequent patients will receive cell infusions in escalating cell doses. A minimum of two months will be used as an interval between ECP-DL treatment in each tier. A staggered approach for moving to the next tier will be employed waiting no less than two months to ensure absence of adverse events using the following tier dosing schema:

Tier 1: 0.5 x 10\^9 ECP-DL treated cells (n=4) Tier 2: 1 x 10\^9 ECP-DL treated cells (n=4) Tier 3: 2 x 10\^9 ECP-DL treated cells (n=4)

Following transplant, LDK recipients will undergo ECP using the Therakos system on two consecutive days per month for 6 months (12 treatments). Peripheral IV access will be used whenever possible.

02

Conditions studied

  • Kidney Transplant Failure and Rejection
  • Kidney Transplant; Complications
03

In context

Lead sponsor

Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.

Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipient age ≥30 and less than 70 years old.
  • Donor age ≥18 and ≤ 70 years old.
  • Recipient of a first kidney transplant from a living unrelated or living related donor that is not HLA-identical to the donor.
  • Donor willing to undergo cell collection for ECP-DL cell preparation and infusion.
  • Donors will be screened and tested for -1 (antigen and nucleic acid), HIV-2, virus (HBV, nucleic acid and surface and core antigen), virus (HCV, antigen and nucleic acid), Treponema pallidum (syphilis), West Nile Virus (WNV), and CJD (screening only). and tested for human T-lymphotropic virus types 1 and 2 (HTLV-1, HTLV-2) and CMV, in accordance with established UNOS guidelines for solid organ donors.
  • Donors and recipients who test negative for TB using QuantiFERON gold assay.
  • Must be willing and able to comply with protocol-required visit schedule and visit requirement.
  • Patients who are single-organ recipients (kidney only).
  • Women who are of must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of throughout the treatment period. Both male and female transplant recipients must agree to the use of highly effective birth control for 12 months following ECP-DL procedure. Individuals unwilling to do so will be excluded from study participation.
  • Subjects are able to understand the consent form and give written .

Exclusion criteria

Exclusion Criteria:

RECIPIENT

  • Known sensitivity or to everolimus, tacrolimus, or psoralen.
  • Aphakia.
  • Has undergone splenectomy
  • Patients with light-sensitive diseases including (but not limited to) systemic lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porhyria, xeroderma pigmentosum, and albinism
  • Patient with significant or active infection.
  • Patients with a positive flow cytometric crossmatch using donor lymphocytes and recipient serum.
  • Patients with PRA >80%
  • Patients with current or historic donor specific antibodies
  • (BMI) of \< 18 or > 40
  • Patients who are pregnant or nursing mothers
  • Patients whose is severely limited by diseases other than renal disease
  • Ongoing active substance abuse, drug or alcohol
  • Major ongoing psychiatric illness or recent history of noncompliance
  • Significant cardiovascular disease
  • within 3 years, excluding nonmelanoma skin cancers
  • Subjects with cerebrovascular vascular disease with recent (\< 6 months) stroke
  • Serologic evidence of infection with or HBVs Ag positive
  • Recipient is EBV serologic negative
  • Donor CMV serologic positive to recipient CMV serologic negative
  • Recipient tests positive for viral load by PCR
  • Patients with a screening/baseline total white blood cell count \< 4,000/mm3; count \< 100,000/mm3; triglyceride > 400 mg/dl; total cholesterol > 300 mg/dl
  • drug within 30 days prior to transplant surgery
  • Anti-T cell therapy within 30 days prior to transplant surgery
  • Documented severe liver disease, defined as bridging fibrosis or cirrhosis on liver
  • Poorly controlled diabetes, defined as of > 8.0
  • > 2.0
  • SBP \< 90 or > 180mm Hg, HR > 120 or \<50bpm, Temp > 99.5F on day of proposed ECP-DL procedure
  • Patients receiving concomitant enteral or topical medical therapy with potentially photosensitizing effects

DONOR

  • Lack of possible peripheral IV access (two access sites)
  • Has undergone splenectomy
  • Donor tests positive for HCV viral load by PCR
  • PT/INR > 2.0; or known hyper or hypo coagulable disorders
  • \< 10.0
  • platelet count \< 100,000
  • SBP \< 90 or > 160mm Hg, HR > 120 or \<50bpm, Temp > 99.5F on day of proposed ECP-DL procedure
  • Donors who cannot tolerate extracorporeal volume during PBMC collection
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    ECP-DL Cell Therapy Arm

    Participants will receive escalating doses of ECP-DL (extracorporeal photopheresis-derived dendritic-like) cells starting on Day -7 prior to living donor kidney transplantation. The intervention aims to evaluate the safety and immunomodulatory effects of ECP-DL cell infusion in the context of renal transplantation.

    Device: ECP-DL treated mononuclear cell infusion

Interventions

  • DeviceECP-DL treated mononuclear cell infusion

    Participants in this study will undergo the infusion of donor white blood cells treated with ECP one week before their living donor kidney transplant, combined with standard of care antirejection medications. You will also then have ECP treatments using your own blood on two consecutive days once per month for 6 months. This combination is intended to cause your immune system to create a state called tolerance to the donor kidney. The ECP procedure has not been approved to prevent rejection after kidney transplant and the use of ECP to prevent rejection of transplanted organs is experimental, and is not a part of standard treatment which is based on the long term use of anti-rejection drugs such as tacrolimus (Prograf), everolimus, and prednisone.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Following Escalating Doses of ECP-DL Cells

    To determine the safety profile of escalating doses of ECP-DL cells administered to patients undergoing living donor kidney transplantation.

    Time frame: From Day -7 (first ECP-DL infusion) through 24 months post transplant

Secondary outcomes

  1. Incidence of Transplant-Related Adverse Events

    To assess the frequency and type of adverse events associated with renal transplantation and immunosuppressive therapy.

    Time frame: Baseline through 24 months post-transplant.

  2. Incidence and Severity of Infections

    To evaluate the incidence, timing, and severity of bacterial, viral, and fungal infections post-transplant.

    Time frame: Baseline through 24 months post-transplant

  3. Changes in Peripheral Blood Lymphocyte Subpopulations

    To assess changes in lymphocyte subpopulations, including regulatory T cells and effector T cells, following ECP-DL infusion.

    Time frame: Baseline, Day 0, Day 7, Day 30, and Month 6

  4. Change in Donor-Specific T Cell Response as Measured by Mixed Lymphocyte Reaction (MLR) and ELISPOT Assays

    Donor-specific hyporesponsiveness will be assessed by measuring the proliferation of recipient peripheral blood mononuclear cells (PBMCs) in response to donor antigens using Mixed Lymphocyte Reaction (MLR), and by quantifying interferon-gamma (IFN-γ) producing cells using ELISPOT assays. Results will be reported as stimulation index (SI) for MLR and spot-forming units (SFU) per 10\^6 PBMCs for ELISPOT.

    Time frame: Baseline, Day 30, and Month 6

  5. Quantitative Changes in Plasma and Urine Proteins Identified by Mass Spectrometry-Based Proteomic Analysis

    Blood and urine samples will be analyzed using mass spectrometry to measure changes in protein levels related to ECP-DL treatment and transplant outcomes. Protein levels will be reported using standard lab methods, and changes over time will be compared to identify significant differences.

    Time frame: Baseline, Day 30, and Month 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2029, 34 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Jan 2027, primary completion Dec 2028 → Dec 2029 and completion Aug 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 24, 2025
StartEst.
Jan 30, 2027was Aug 2026
Primary completionEst.
Dec 25, 2029was Dec 2028
CompletionEst.
Dec 25, 2029was Aug 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 30, 2026→Jan 30, 2027
Nov 2, 2026
Primary completion
Dec 25, 2028→Dec 25, 2029
Nov 2, 2026
Study completion
Aug 25, 2029→Dec 25, 2029
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Aug 30, 2026→Jan 30, 2027
    Primary completion Dec 25, 2028→Dec 25, 2029
    Study completion Aug 25, 2029→Dec 25, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07083830
Responsible party
Joseph Leventhal (Professor, Northwestern University) — Principal investigator
First posted
Jul 24, 2025
Start date
Jan 30, 2027 (estimated)
Primary completion
Dec 25, 2029 (estimated)
Completion
Dec 25, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Erica Cuasay (RN)
Contact
erica.cuasay@northwestern.edu
312-926-1076
Joseph Leventhal, MD, PhD
principal investigator · Northwestern University
Jennifer Schneiderman, MD, MS
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion